Education
About Us
Working with TipRanks
Follow Us
Transmedics Group (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
$134.77
-$4.08(-5.19%)
At close: 4:00 PM EST
$134.77
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$62.23 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)823.86K
Market Cap
$4.49B
Enterprise Value$4.47B
Total Cash (Recent Filing)$488.37M
Total Debt (Recent Filing)$469.69M
Price to Earnings (P/E)21.7
Beta1.12
Next Earnings
May 05, 2026EPS Estimate
0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.62
Shares Outstanding34,302,452
10 Day Avg. Volume1,176,044
30 Day Avg. Volume823,857
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.74
Price to Sales (P/S)6.83
P/FCF Ratio30.96
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue7.38
Enterprise Value/Gross Profit12.32
Enterprise Value/Ebitda30.10
Forecast
1Y Price Target
$160.30Price Target Upside18.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)2.48
Revenue Forecast (FY)$737.49M
Bulls Say, Bears Say
Bulls Say
Clinical Trial Approvals And EnrollmentFull IDE approvals for next-generation heart and lung studies enable unrestricted patient enrollment and could accelerate commercial uptake if trial-related sales ramp faster than management projections.
DCD Adoption And Transport UtilizationRising donation-after-circulatory-death liver transplants and record flight hours for transport services point to expanding use of the organ preservation system and higher service revenue.
Guidance And Revenue BeatRevenue beat combined with management revenue guidance above consensus signals stronger-than-expected demand in the U.S. transplant business and supports upside to sales.
Bears Say
Competitive And Commercial RisksAcquisition of a competing organ preservation technology by a large medical equipment company and surgeon concerns about pricing sustainability raise questions about future market share and pricing power.
Earnings QualityThe large reported earnings beat was driven by a one-time tax-related gain, reducing how representative the profit surprise is of core operating performance.
Margin Pressure From Trial SpendingPlanned spending on clinical trials and new product development is expected to compress operating margins and weigh on near-term profitability.
TransMedics Group News
TMDX FAQ
What was Transmedics Group’s price range in the past 12 months?
Transmedics Group lowest stock price was $62.23 and its highest was $156.00 in the past 12 months.
What is Transmedics Group’s market cap?
Transmedics Group’s market cap is $4.49B.
When is Transmedics Group’s upcoming earnings report date?
Transmedics Group’s upcoming earnings report date is May 05, 2026 which is in 55 days.
How were Transmedics Group’s earnings last quarter?
Transmedics Group released its earnings results on Feb 27, 2026. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $0.436 by $2.184.
Is Transmedics Group overvalued?
According to Wall Street analysts Transmedics Group’s price is currently Undervalued.
Does Transmedics Group pay dividends?
Transmedics Group does not currently pay dividends.
What is Transmedics Group’s EPS estimate?
Transmedics Group’s EPS estimate is 0.64.
How many shares outstanding does Transmedics Group have?
Transmedics Group has 34,302,452 shares outstanding.
What happened to Transmedics Group’s price movement after its last earnings report?
Transmedics Group reported an EPS of $2.62 in its last earnings report, beating expectations of $0.436. Following the earnings report the stock price went up 1.198%.
Which hedge fund is a major shareholder of Transmedics Group?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$160.30 (18.94% Upside)
$160.30 (18.94% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Bullish
Bullish news 79%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
99.77%
12-Months-Change
Fundamentals
Return on Equity
53.88%
Trailing 12-Months
Asset Growth
35.04%
Trailing 12-Months
Company Description
Transmedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and financial momentum: robust revenue growth (Q4 +32% YoY; FY +37%), expanded operating margins, a healthy cash balance (~$488M), large increases in OCS clinical volume (5,139 U.S. OCS transplants in 2025) and clear growth catalysts across clinical programs, next-generation platforms and international rollout. Notable near-term risks include Q4 gross margin pressure, a significant one-time tax benefit inflating net income, low lung adoption, potential trial delays due to competitive dynamics in ENHANCE Part B, and planned 2026 investments that will compress margins temporarily. On balance, the positives — scalable revenue growth, margin expansion at scale, strong cash position and accelerating clinical adoption in liver and heart — outweigh the lowlights, though execution on trials, international buildout and operational scaling remains critical.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$160.30
▲(18.94% Upside)
Technical Analysis
Ownership Overview
3.59% Insiders
43.50% Mutual Funds
8.25% Other Institutional Investors
20.81% Public Companies and Individual Investors